tiprankstipranks
PHC Holdings Corp. (JP:6523)
:6523
Want to see JP:6523 full AI Analyst Report?

PHC Holdings Corp. (6523) AI Stock Analysis

1 Followers

Top Page

JP:6523

PHC Holdings Corp.

(6523)

Select Model
Select Model
Select Model
Neutral 47 (OpenAI - 5.2)
Rating:47Neutral
Price Target:
¥1,043.00
▼(-6.21% Downside)
Action:Reiterated
Date:05/15/26
The score is held down primarily by unstable earnings (near break-even in 2026 after a strong 2025) and still-elevated leverage despite improvement, with technical indicators also bearish as the price sits below key moving averages and momentum gauges are negative. Positive and improving free cash flow and a ~4.23% dividend yield provide partial support, but the very high P/E (279.9) keeps the valuation component weak.
Positive Factors
Revenue growth acceleration
A sustained step-up to +12.9% revenue growth signals strengthening end-market demand and improving product mix across diagnostics, life‑science and medical equipment. This revenue momentum supports scale, broadens installed bases and underpins longer‑term cash flow and reinvestment capacity.
Negative Factors
Profitability volatility
Large swings from multi‑year losses to a one‑year profit and back toward break‑even indicate unstable operating performance. This volatility complicates long‑range planning, weakens returns on invested capital, and raises execution risk for sustaining margins and funding reinvestment without recurring earnings consistency.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth acceleration
A sustained step-up to +12.9% revenue growth signals strengthening end-market demand and improving product mix across diagnostics, life‑science and medical equipment. This revenue momentum supports scale, broadens installed bases and underpins longer‑term cash flow and reinvestment capacity.
Read all positive factors

PHC Holdings Corp. (6523) vs. iShares MSCI Japan ETF (EWJ)

PHC Holdings Corp. Business Overview & Revenue Model

Company Description
PHC Holdings Corporation, through its network of subsidiaries, specializes in the innovation, production, and sale of medical instruments, advanced healthcare technology solutions, and life science merchandise. The company's product line includes ...
How the Company Makes Money
PHC Holdings primarily generates revenue by selling healthcare products and related services through three major business areas. (1) Diagnostics: the company sells in-vitro diagnostic instruments (e.g., clinical analyzers and point-of-care devices...

PHC Holdings Corp. Financial Statement Overview

Summary
Revenue growth is improving (latest year +12.9%) and free cash flow has stayed positive even in loss years, but profitability has been highly volatile (losses in 2022–2024, strong profit in 2025, near break-even in 2026). Leverage is improving (debt-to-equity down to ~1.45x) yet remains meaningful, and returns are currently very low (~0.3% ROE).
Income Statement
44
Neutral
Balance Sheet
41
Neutral
Cash Flow
63
Positive
BreakdownMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue364.40B361.59B353.90B356.43B340.45B
Gross Profit165.26B166.22B157.97B169.13B165.24B
EBITDA47.72B52.33B30.15B36.76B37.56B
Net Income492.00M10.48B-12.89B-3.22B-8.46B
Balance Sheet
Total Assets542.51B532.48B564.33B561.57B591.32B
Cash, Cash Equivalents and Short-Term Investments39.82B43.90B51.82B63.25B97.63B
Total Debt234.56B269.26B300.28B307.24B323.32B
Total Liabilities381.63B391.31B425.16B422.74B455.25B
Stockholders Equity161.67B141.64B139.51B138.01B135.37B
Cash Flow
Free Cash Flow33.37B30.33B26.67B9.86B39.32B
Operating Cash Flow42.46B41.94B41.30B21.38B51.05B
Investing Cash Flow-8.45B-8.47B-23.68B-17.52B-12.52B
Financing Cash Flow-39.82B-39.07B-36.53B-40.83B-7.01B

PHC Holdings Corp. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1112.00
Price Trends
50DMA
1043.76
Negative
100DMA
1048.25
Negative
200DMA
1036.89
Negative
Market Momentum
MACD
-5.35
Positive
RSI
34.74
Neutral
STOCH
8.05
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6523, the sentiment is Negative. The current price of 1112 is above the 20-day moving average (MA) of 1068.95, above the 50-day MA of 1043.76, and above the 200-day MA of 1036.89, indicating a bearish trend. The MACD of -5.35 indicates Positive momentum. The RSI at 34.74 is Neutral, neither overbought nor oversold. The STOCH value of 8.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6523.

PHC Holdings Corp. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
¥16.64B12.503.02%13.43%7.14%
67
Neutral
¥8.39B10.871.89%6.09%-6.33%
61
Neutral
¥231.16B15.761.92%4.29%3.92%
56
Neutral
¥84.00B22.452.31%3.35%74.41%
54
Neutral
¥23.99B91.783.12%-4.77%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
47
Neutral
¥128.08B261.302.42%3.73%0.78%-95.37%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:6523
PHC Holdings Corp.
1,007.00
144.95
16.81%
JP:4549
Eiken Chemical Co., Ltd.
2,526.00
454.52
21.94%
JP:6678
Techno Medica Co., Ltd.
1,941.00
155.20
8.69%
JP:6849
Nihon Kohden Corporation
1,400.50
-281.62
-16.74%
JP:7600
Japan Medical Dynamic Marketing, Inc.
905.00
351.74
63.57%
JP:7963
Koken Ltd.
1,690.00
-3.56
-0.21%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 15, 2026